Production (Stage)
AnaptysBio, Inc.
ANAB
$20.44
-$0.30-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 286.84% | 378.77% | 804.67% | 217.08% | 422.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 286.84% | 378.77% | 804.67% | 217.08% | 422.49% |
| Cost of Revenue | 11.17% | 27.04% | 36.71% | 27.56% | 5.96% |
| Gross Profit | 55.10% | 102.14% | 55.75% | -5.30% | 11.08% |
| SG&A Expenses | 14.52% | -0.80% | 3.83% | -12.97% | 14.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.01% | 20.51% | 28.56% | 17.63% | 7.88% |
| Operating Income | 34.74% | 72.21% | 39.69% | -0.44% | 4.95% |
| Income Before Tax | 10.59% | 48.38% | 11.95% | -17.08% | 0.72% |
| Income Tax Expenses | -- | -50.00% | -- | -- | -- |
| Earnings from Continuing Operations | 10.49% | 48.39% | 11.95% | -17.10% | 0.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.49% | 48.39% | 11.95% | -17.10% | 0.72% |
| EBIT | 34.74% | 72.21% | 39.69% | -0.44% | 4.95% |
| EBITDA | 34.84% | 72.50% | 39.82% | -0.47% | 4.97% |
| EPS Basic | 21.71% | 54.94% | 19.10% | -13.99% | -3.54% |
| Normalized Basic EPS | 21.80% | 45.44% | 19.10% | -13.96% | -3.55% |
| EPS Diluted | 21.71% | 54.94% | 19.10% | -13.99% | -3.54% |
| Normalized Diluted EPS | 21.80% | 45.44% | 19.10% | -13.96% | -3.55% |
| Average Basic Shares Outstanding | 14.34% | 14.53% | 8.84% | 2.73% | -4.12% |
| Average Diluted Shares Outstanding | 14.34% | 14.53% | 8.84% | 2.73% | -4.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |